In the analysis of ABCA1 expression and anti-tumor drug sensitivity, we found that patients in the high-ABCA1 group had a higher half maximal inhibitory concentration (IC50) for cisplatin (P < 0.001), etoposide (P < 0.001), mitomycin C (P < 0.001), and sorafenib (P < 0.05) compared to patients in the low-ABCA1 group (Fig. 6a–d). The gene discussed is ABCA1; the disease is neoplasm.